SCHEMBL6357916

SCHEMBL6357916

O=C1CC(c2cc(F)cc(F)c2)CC(=O)O1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 1/20 0.39
CYP19A1 P11511 1/20 0.36
PLAU P00749 2/20 0.34
HCAR2 Q8TDS4 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SIRT2 Q8IXJ6 2/20 0.33
GRM2 Q14416 1/20 0.32
MAP1LC3B Q9GZQ8 1/20 0.31
TP53 P04637 1/20 0.31
MAOB P27338 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31462691 0.87 TRPM5 (0.35) CTRB1MEN1KMT2ATP53
SCHEMBL6265155 0.83 ALDH1A1 (0.40) MEN1ALDH1A1KMT2AMAOB
SCHEMBL31560367 0.82 CTRB1 (0.38) CTRB1PLAUSIRT2
SCHEMBL5856736 0.81 KDM4E (0.47) CTRB1CYP19A1HCAR2KDM4EMEN1
SCHEMBL658679 0.79 MAP1LC3B (0.49) CTRB1PLAUALDH1A1KMT2ASIRT2
SCHEMBL7105128 0.75 CTRB1 (0.39) CTRB1PLAUMEN1ALDH1A1KMT2A
SCHEMBL10017608 0.75 CTRB1 (0.53) CTRB1PLAUALDH1A1SMN1; SMN2MAP1LC3B
SCHEMBL6048200 0.75 SIRT2 (0.45) CTRB1PLAUHCAR2SIRT2
SCHEMBL12371035 0.74 NPY5R (0.33) CYP19A1GRM2
SCHEMBL6261980 0.72 MAPT (0.37) CYP19A1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025076088-A1 LACTAMS FOR USE AS SARM1 INHIBITORS GENENTECH, INC. (US) 2025-04-10 WO disclosed
US-20050043344-A1 Heteroarylalkanoic acids as integrin receptor antagonists derivatives PHARMACIA CORPORATION 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043344-A1 Heteroarylalkanoic acids as integrin receptor antagonists derivatives ITGA5, ITGAV, ITGA6 CTRB1 3499/4885CYP19A1 4762/4885PLAU 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.